Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals - the Swiss HIV Cohort Study

Journal of Translational Medicine

Volumn 9, Issue , 2011, Pages

  Fehr, Jan ^a   Glass, Tracy R ^b   Louvel, Séverine ^c,d   Hamy, François ^c   Hirsch, Hans H ^a,d   von Wyl, Viktor ^e   Böni, Jürg ^f   Yerly, Sabine ^g   Bürgisser, Philippe ^h   Cavassini, Matthias ^h   Fux, Christoph A ⁱ   Hirschel, Bernard ^g   Vernazza, Pietro ^j   Martinetti, Gladys ^k   Bernasconi, Enos ^k   Günthard, Huldrych F ^e   Battegay, Manuel ^a   Bucher, Heiner C ^b   Klimkait, Thomas ^d  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c InPheno AG   (Switzerland)

^d UNIVERSITY OF BASEL   (Switzerland)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f Swiss National Centre for Retroviruses   (Switzerland)

^g UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^h LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

ⁱ UNIVERSITY OF BERN   (Switzerland)

^j CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^k Ospedale Civico Lugano   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PHENOTYPE; VIRUS DETECTION; VIRUS DIAGNOSIS; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE; CLINICAL TRIAL; COHORT ANALYSIS; DOSE RESPONSE; DRUG EFFECT; EVALUATION; HUMAN IMMUNODEFICIENCY VIRUS 1; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MIDDLE AGED; MULTICENTER STUDY; PHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; SWITZERLAND; VIROLOGY;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SWITZERLAND; VIRUS REPLICATION;

EID: 78651549838     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-14     Document Type: Article

References (41)

1. The Antiretroviral Therapy Cohort Collaboration Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. The Lancet 2008, 372:293-9. The Antiretroviral Therapy Cohort Collaboration.
2. Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA, . ART Cohort Collaboration Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. The Lancet 2002, 360:119-29. ART Cohort Collaboration.
3. Lima VD, Hogg RS, Harrigan PR, Moore D, Yip B, Wood E, Montaner JS. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 2007, 21:685-92. 10.1097/QAD.0b013e32802ef30c, 17413689.
4. May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, Dabis F, Gill J, Lundgren J, Hogg RS, de Wolf F, Fätkenheuer G, Staszewski S, d'Arminio Monforte A, Egger M. Antiretroviral Therapy (ART) Cohort Collaboration. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. The Lancet 2006, 368:451-8.
5. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. The New England journal of medicine 1998, 338:853-60. 10.1056/NEJM199803263381301, 9516219.
6. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services DHHS 2009, 1-161. Panel on Antiretroviral Guidelines for Adults and Adolescents., http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf
7. European AIDS Clinical Society Guidelines Guidelines for the Clinical Management and Treatment of HIV-infected Adults in Europe. EACS-guidelines 2009, Version 5, European AIDS Clinical Society Guidelines., http://www.europeanaidsclinicalsociety.org/guidelines.asp
8. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, Gatell JM, Günthard HF, Hammer SM, Hirsch MS, Jacobsen DM, Reiss P, Richman DD, Volberding PA, Yeni P, Schooley RT, . International AIDS Society-USA Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010, 21(304 (3)):321-33. International AIDS Society-USA.
9. Hirsch MS, Günthard HF, Schapiro JM, Brun-Vézinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM, Richman DD, . International AIDS Society-USA Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008, 47:266-85. 10.1086/589297, 18549313, International AIDS Society-USA.
10. Günthard HF, Wong JK, Ignacio CC, Havlir DV, Richman DD. Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. AIDS Res Hum Retroviruses 1998, 14:869-876. 10.1089/aid.1998.14.869, 9671215.
11. Schuurman R, Brambilla D, de Groot T, Huang D, Land S, Bremer J, Benders I, Boucher CA. Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. AIDS Res Hum Retroviruses 2002, 18:243-248. 10.1089/088922202753472801, 11860670.
12. Bacheler L, Jeffrey S, Hanna G, D'Aquila R, Wallace L, Logue K, Cordova B, Hertogs K, Larder B, Buckery R, Baker D, Gallagher K, Scarnati H, Tritch R, Rizzo C. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 2001, 75:4999-5008. 10.1128/JVI.75.11.4999-5008.2001, 114903, 11333879.
13. Beerenwinkel N, Däumer M, Oette M, Korn K, Hoffmann D, Kaiser R, Lengauer T, Selbig J, Walter H, . Geno2pheno Estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res 2003, 31:3850-5. 10.1093/nar/gkg575, 168981, 12824435, Geno2pheno.
14. Mazzotta F, Lo Caputo S, Torti C, Tinelli C, Pierotti P, Castelli F, Lazzarin A, Angarano G, Maserati R, Gianotti N, Ladisa N, Quiros-Roldan E, Rinehart AR, Carosi G. Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial. Journal of acquired immune deficiency syndromes 2003, 32:268-80. 10.1097/00126334-200303010-00005, 12626886.
15. Perez-Elias MJ, Garcia-Arota I, Muñoz V, Santos I, Sanz J, Abraira V, Arribas JR, González J, Moreno A, Dronda F, Antela A, Pumares M, Martí-Belda P, Casado JL, Geijos P, Moreno S. Phenotype or virtual phenotype for choosing antiretroviral therapy after failure: a prospective, randomized study. Antiviral therapy 2003, 8:577-84.
16. Holguin A, Sune C, Hamy F, Soriano V, Klimkait T. Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure. J Clin Virol 2006, 36:264-71. 10.1016/j.jcv.2006.05.001, 16765636.
17. Klimkait T. A sensitive replicative system to assess HIV-1 drug resistance. American clinical laboratory 2002, 21:20-4.
18. Louvel S, Battegay M, Vernazza P, Bregenzer T, Klimkait T, Hamy F. Detection of drug-resistant HIV minorities in clinical specimens and therapy failure. HIV Med 2008, 9:133-41. 10.1111/j.1468-1293.2007.00529.x, 18218003.
19. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP, Merigan TC. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 2000, 14:F83-F93. 10.1097/00002030-200006160-00001, 10894268.
20. Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, Baldini F, Di Giambenedetto S, Cauda R, De Luca A. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 2002, 16:369-79. 10.1097/00002030-200202150-00008, 11834948.
21. Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, Del Giudice P, Montagne N, Schapiro JM, Dellamonica P. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. The Lancet 1999, 353:2195-9.
22. Haupts S, Ledergerber B, Böni J, Schüpbach J, Kronenberg A, Opravil M, Flepp M, Speck RF, Grube C, Rentsch K, Weber R, Günthard HF, . Swiss HIV Cohort Study Impact of genotypic resistance testing on selection of salvage regimen in clinical practice. Antiviral therapy 2003, 8:443-54. Swiss HIV Cohort Study.
23. Sendi P, Gunthard HF, Simcock M, Ledergerber B, Schupbach J, Battegay M. Cost-Effectiveness of Genotypic Antiretroviral Resistance Testing in HIV-Infected Patients with Treatment Failure. PLoS ONE 2007, 2:e173. 10.1371/journal.pone.0000173, 1769464, 17245449.
24. Simcock M, Sendi P, Ledergerber B, Keller T, Schüpbach J, Battegay M, Günthard HF, . Swiss HIV Cohort Study A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?. Antiviral therapy 2006, 11:305-14. Swiss HIV Cohort Study.
25. Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, González J, Domingo P, Boucher C, Rey-Joly C, Clotet B. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002, 16:209-18. 10.1097/00002030-200201250-00010, 11807305.
26. Cohen CJ, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, Nadler J, Verbiest W, Hertogs K, Ames M, Rinehart AR, Graham NM. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002, 16:579-88. 10.1097/00002030-200203080-00009, 11873001.
27. Hales G, Birch C, Crowe S, Workman C, Hoy JF, Law MG, Kelleher AD, Lincoln D, Emery S. A Randomised Trial Comparing Genotypic and Virtual Phenotypic Interpretation of HIV Drug Resistance: The CREST Study. PLoS clinical trials 2006, 1:18-e.
28. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, Matheron S, Lamotte C, Guiramand S, Costagliola D, Brun-Vézinet F, Clavel F, Girard PM, . Narval Trial Group Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 2002, 16:727-36. 10.1097/00002030-200203290-00008, 11964529, Narval Trial Group.
29. Wegner SA, Wallace MR, Aronson NE, Tasker SA, Blazes DL, Tamminga C, Fraser S, Dolan MJ, Stephan KT, Michael NL, Jagodzinski LL, Vahey MT, Gilcrest JL, Tracy L, Milazzo MJ, Murphy DJ, McKenna P, Hertogs K, Rinehart A, Larder B, Birx DL. Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial. Clin Infect Dis 2004, 38:723-30. 10.1086/381266, 14986258.
30. Dunn DT, Green H, Loveday C, Rinehart A, Pillay D, Fisher M, McCormack S, Babiker AG, Darbyshire JH. A randomized controlled trial of the value of phenotypic testing in addition to genotypic testing for HIV drug resistance: evaluation of resistance assays (ERA) trial investigators. J Acquir Immune Defic Syndr 2005, 38:553-9. 10.1097/01.qai.0000148533.12329.96, 15793365.
31. Hirsch HH, Drechsler H, Holbro A, Hamy F, Sendi P, Petrovic K, Klimkait T, Battegay M. Genotypic and phenotypic resistance testing of HIV-1 in routine clinical care. European journal of clinical microbiology & infectious diseases 2005, 24:733-8.
32. Swiss HIV Cohort Study Ongoing multicenter research. Swiss HIV Cohort Study., http://http//:www.shcs.ch
33. von Wyl V, Yerly S, Böni J, Bürgisser P, Klimkait T, Battegay M, Furrer H, Telenti A, Hirschel B, Vernazza PL, Bernasconi E, Rickenbach M, Perrin L, Ledergerber B, Günthard HF. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med 2007, 167:1782-90. 10.1001/archinte.167.16.1782, 17846398.
34. Yerly S, Vora S, Rizzardi P, Chave JP, Vernazza PL, Flepp M, Telenti A, Battegay M, Veuthey AL, Bru JP, Rickenbach M, Hirschel B, Perrin L. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS 2001, 15:2287-92. 10.1097/00002030-200111230-00010, 11698702.
35. Klimkait T, Stauffer F, Lupo E, Sonderegger-Rubli C. Dissecting the mode of action of various HIV-inhibitor classes in a stable cellular system. Arch Virol 1998, 143:2109-31. 10.1007/s007050050447, 9856097.
36. Glass TR, Battegay M, Cavassini M, De Geest S, Furrer H, Vernazza PL, Hirschel B, Bernasconi E, Rickenbach M, Günthard HF, Bucher HC, . Swiss HIV Cohort Study Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2010, 54(2):197-203. Swiss HIV Cohort Study.
37. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007, 335:806-8. 10.1136/bmj.39335.541782.AD, 2034723, 17947786.
38. von Wyl V, Yerly S, Bürgisser P, Klimkait T, Battegay M, Bernasconi E, Cavassini M, Furrer H, Hirschel B, Vernazza PL, Francioli P, Bonhoeffer S, Ledergerber B, Günthard HF. Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. Clin Infect Dis 2009, 48:979-87. 10.1086/597352, 19228107.
39. Briones C, Domingo E. Minority report: hidden memory genomes in HIV-1 quasispecies and possible clinical implications. AIDS Rev 2008, 10:93-109.
40. Rozera G, Abbate I, Bruselles A, Vlassi C, D'Offizi G, Narciso P, Chillemi G, Prosperi M, Ippolito G, Capobianchi MR. Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte sub-populations. Retrovirology 2009, 6:15. 10.1186/1742-4690-6-15, 2660291, 19216757.
41. Snoeck J, Kantor R, Shafer RW, Van Laethem K, Deforche K, Carvalho AP, Wynhoven B, Soares MA, Cane P, Clarke J, Pillay C, Sirivichayakul S, Ariyoshi K, Holguin A, Rudich H, Rodrigues R, Bouzas MB, Brun-Vézinet F, Reid C, Cahn P, Brigido LF, Grossman Z, Soriano V, Sugiura W, Phanuphak P, Morris L, Weber J, Pillay D, Tanuri A, Harrigan RP, Camacho R, Schapiro JM, Katzenstein D, Vandamme AM. Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob Agents Chemother 2006, 50:694-701. 10.1128/AAC.50.2.694-701.2006, 1366873, 16436728.